SCHEMBL23924927

SCHEMBL23924927

COC[C@@H](Nc1c(N)cnc2ccccc12)C(C)(C)C

nearest known ligand 0.46

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
LRRK2 Q5S007 1/20 0.38
LDHA P00338 1/20 0.36
NCF1 P14598 2/20 0.34
PDE4B Q07343 1/20 0.33
ATM Q13315 1/20 0.33
TP53 P04637 3/20 0.33
MAPT P10636 3/20 0.33
SMN1; SMN2 Q16637 2/20 0.33
MEN1 O00255 1/20 0.33
PKM P14618 1/20 0.33
KMT2A Q03164 1/20 0.33
MPO P05164 1/20 0.32
GRM5 P41594 1/20 0.32
KDM1A O60341 1/20 0.31
SUMO3 P55854 1/20 0.31
SUMO2 P61956 1/20 0.31
SUMO1 P63165 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23924929 1.00 LRRK2 (0.38) LRRK2LDHANCF1PDE4BATM
SCHEMBL23924991 0.88 LRRK2 (0.36) LRRK2NCF1ATMTP53MAPT
SCHEMBL23924989 0.88 LRRK2 (0.36) LRRK2NCF1ATMTP53MAPT
SCHEMBL5270377 0.82 LRRK2 (0.38) LRRK2NCF1ATMTP53MAPT
SCHEMBL23924802 0.82 SMN1; SMN2 (0.38) LRRK2MAPTSMN1; SMN2MEN1KMT2A
SCHEMBL23924804 0.82 SMN1; SMN2 (0.38) LRRK2MAPTSMN1; SMN2MEN1KMT2A
SCHEMBL29508372 0.81 TLR8 (0.40) LRRK2PDE4BSMN1; SMN2
SCHEMBL1034069 0.79 MEN1 (0.36) LRRK2PDE4BTP53MAPTSMN1; SMN2
SCHEMBL21994851 0.79 KMT2A (0.37) LRRK2NCF1TP53MAPTSMN1; SMN2
SCHEMBL21994850 0.79 KMT2A (0.37) LRRK2NCF1TP53MAPTSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12540137-B2 N-1 branched alkyl ether substituted imidazo[4,5-c]quinoline compounds, compositions, and methods SOLVENTUM INTELLECTUAL PROPERTIES COMPANY (US) 2026-02-03 US disclosed
US-20240300947-A1 N-1 Branched Alkyl Ether Substituted Imidazo[4,5-c]Quinoline Compounds, Compositions, and Methods SOLVENTUM INTELLECTUAL PROPERTIES COMPANY (US) 2024-09-12 US disclosed
US-12024514-B2 N-1 branched alkyl ether substituted imidazo[4,5-c]quinoline compounds, compositions, and methods SOLVENTUM INTELLECTUAL PROPERTIES COMPANY (US) 2024-07-02 US disclosed
CN-113166143-B N-1 branched alkyl ether substituted imidazo [4,5-c ] quinoline compounds, compositions and methods 舒万诺知识产权公司 2024-06-04 CN disclosed
EP-3887369-B1 N-1 BRANCHED ALKYL ETHER SUBSTITUTED IMIDAZO[4,5-C]QUINOLINE COMPOUNDS, COMPOSITIONS, AND METHODS SOLVENTUM INTELLECTUAL PROPERTIES COMPANY (US) 2024-05-08 EP disclosed
US-20210323962-A1 N-1 BRANCHED ALKYL ETHER SUBSTITUTED IMIDAZO[4,5-C]QUINOLINE COMPOUNDS, COMPOSITIONS, AND METHODS SOLVENTUM INTELLECTUAL PROPERTIES COMPANY 2021-10-21 US disclosed
CN-113166143-A N-1 branched alkyl ether substituted imidazo [4,5-c ] quinoline compounds, compositions, and methods 3M创新有限公司 2021-07-23 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12540137-B2 N-1 branched alkyl ether substituted imidazo[4,5-c]quinoline compounds, compositions, and methods IRF3, IFNAR1, IFNG LRRK2 1295/4885LDHA 331/4885NCF1 1438/4885
US-20240300947-A1 N-1 Branched Alkyl Ether Substituted Imidazo[4,5-c]Quinoline Compounds, Compositions, and Methods IFNG, IFNAR1, IRF3 LRRK2 3506/4885LDHA 2874/4885NCF1 81/4885
US-20210323962-A1 N-1 BRANCHED ALKYL ETHER SUBSTITUTED IMIDAZO[4,5-C]QUINOLINE COMPOUNDS, COMPOSITIONS, AND METHODS IFNG, IFNAR1, IRF3 LRRK2 2912/4885LDHA 2867/4885NCF1 95/4885
US-12024514-B2 N-1 branched alkyl ether substituted imidazo[4,5-c]quinoline compounds, compositions, and methods IFNG, IFNAR1, IRF3 LRRK2 2912/4885LDHA 2867/4885NCF1 95/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.